Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety, tolerability, metabolism, and elimination study of INE963 in malaria
NL-OMON59987Phase 1Completed
- Sponsor
- Novartis
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of INE963 in malaria, sponsored by Novartis. Primary endpoint: Primary endpoint(s) not publicly disclosed. Started May 2025; status: completed.
02
Drugs
INE963
03
Conditions
malaria
Beyond the preview
Go deeper on NL-OMON59987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59987.